UK launch of generic lenalidomide for myeloma
pharmafile | January 19, 2022 | News story | Research and Development |
Accord Healthcare have announced the UK launch of generic lenalidomide, available for the treatment of adult patients with multiple myeloma, myelodysplastic syndromes, mantle cell lymphoma, and follicular lymphoma, as either a monotherapy or combination therapy.
Multiple myeloma is a cancer of the plasma cells in bone marrow. This causes bone pain in the chest or spine, fatigue, nausea, constipation, frequent infections, and weight loss. In the early stages, myeloma may not cause any symptoms, and is often only suspected or diagnosed following routine blood or urine tests.
Typical survival of the cancer is seven months without treatment, and four to five years with treatment. There are around 6,000 new myeloma cases in the UK every year, with an increase in incidence rates of a third since the 1990s. Currently, approximately 24,000 people are living with multiple myeloma in the UK.
Accord lenalidomide has been granted Marketing Authorisation by the MHRA, in line with the licensed indications of the brand originator, Revlimid®, and is now available for patients throughout the UK in seven dose strengths ranging from 2.5mg to 25mg.
Lenalidomide is a form of targeted therapy called an angiogenesis inhibitor, and a cancer growth inhibitor. It is also a type of immunotherapy called an immune system modulator. Lenalidomide treatment interferes with chemicals that use cells to signal to each other to grow, and it affects how the immune system works. It also prevents tumours creating their own blood vessels, which all cancers require in order to develop. Lenalidomide must not be used during pregnancy.
To minimize risks associated with this treatment, Accord is overseeing a robust protection system to support safe prescribing, including a strictly monitored Pregnancy Prevention Programme, and an electronic portal for healthcare professional use, facilitating pharmacy registration and prescription authorisation.
Accord lenalidomide will launch in further markets across Europe on 18 February, 2022.